MapLight Therapeutics accelerates Phase 2 enrollment, narrows topline data timing to Q3 2026
California-based MapLight Therapeutics (NASDAQ:MPLT), a clinical-stage biopharmaceutical company focused on novel therapies for neuropsychiatric disorders, provided an update on the progress of its two ongoing Phase 2 studies.





-640x358.jpg&w=3840&q=75)
-640x358.jpg&w=3840&q=75)
-640x358.jpg&w=3840&q=75)
-640x358.jpg&w=3840&q=75)
-640x358.jpg&w=3840&q=75)
-640x358.jpg&w=3840&q=75)